Aclaris Therapeutics Expands Leadership Team
August 01 2022 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced the
appointment of Douglas Manion, M.D., FRCP (C), as President and
Chief Operating Officer. Dr. Manion will be responsible for
overseeing day-to-day operations, continuing to develop Aclaris’
infrastructure and helping Aclaris develop its vision and overall
strategic direction alongside Neal Walker, Aclaris’ CEO, and
Aclaris’ board of directors.
“We are excited to strengthen our leadership team by welcoming
Dr. Manion to Aclaris,” said Dr. Neal Walker, CEO of Aclaris.
“Doug’s significant experience across the business, strong
background in drug development, and track record of leading
organizations, building teams and creating value for both large and
small organizations will be extremely valuable as we continue to
advance our drug development pipeline.”
Dr. Manion brings over 25 years of pharmaceutical industry
experience in both large and small companies. Most recently, he
served as Executive Vice President of Research and Development at
Arena Pharmaceuticals, Inc., where he oversaw all research and
development activities until its acquisition by Pfizer Inc. Prior
to that, Dr. Manion was the Chief Executive Officer of Kleo
Pharmaceuticals, Inc., an immuno-oncology company, until its
acquisition by Biohaven Pharmaceutical Holding Company Ltd. Dr.
Manion’s previous biopharmaceutical experience included leadership
roles at Bristol-Myers Squibb, GlaxoSmithKline, DuPont
Pharmaceuticals and DuPont Merck Pharmaceuticals.
“Aclaris is at an exciting stage in its life, and I am thrilled
to join the organization,” said Dr. Manion. “I look forward to
leveraging my strengths in helping Aclaris grow and execute on its
strategy.”
Dr. Manion’s appointment is effective August 1, 2022. In
connection with his appointment, Dr. Walker will no longer serve as
the President, but will continue to serve as Aclaris’ Chief
Executive Officer.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include the
future contributions of Dr. Manion. These statements involve risks
and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris’ reliance on third parties over which it may not always
have full control, Aclaris’ ability to enter into strategic
partnerships on commercially reasonable terms, the uncertainty
regarding the COVID-19 pandemic and other risks and uncertainties
that are described in the Risk Factors section of Aclaris’ Annual
Report on Form 10-K for the year ended December 31, 2021 and other
filings Aclaris makes with the U.S. Securities and Exchange
Commission from time to time. These documents are available under
the “SEC Filings” page of the “Investors” section of Aclaris’
website at www.aclaristx.com. Any forward-looking statements speak
only as of the date of this press release and are based on
information available to Aclaris as of the date of this release,
and Aclaris assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024